Medtronic (NYSE:MDT) Releases FY 2025 Earnings Guidance

Medtronic (NYSE:MDT - Get Free Report) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 5.440-5.500 for the period, compared to the consensus earnings per share estimate of 5.450. The company issued revenue guidance of $33.5 billion-$33.6 billion, compared to the consensus revenue estimate of $33.6 billion. Medtronic also updated its FY25 guidance to $5.44-5.50 EPS.

Medtronic Stock Performance

NYSE:MDT traded down $2.58 during mid-day trading on Tuesday, hitting $85.01. 9,276,084 shares of the company traded hands, compared to its average volume of 6,257,400. The stock's fifty day moving average price is $89.30 and its 200-day moving average price is $84.84. Medtronic has a one year low of $74.66 and a one year high of $92.68. The company has a quick ratio of 1.61, a current ratio of 2.13 and a debt-to-equity ratio of 0.55. The firm has a market cap of $109.02 billion, a price-to-earnings ratio of 28.72, a price-to-earnings-growth ratio of 2.50 and a beta of 0.84.

Medtronic (NYSE:MDT - Get Free Report) last released its quarterly earnings results on Tuesday, November 19th. The medical technology company reported $1.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.25 by $0.01. Medtronic had a return on equity of 13.68% and a net margin of 12.06%. The business had revenue of $8.40 billion during the quarter, compared to analyst estimates of $8.27 billion. During the same quarter in the previous year, the company posted $1.25 earnings per share. Medtronic's revenue for the quarter was up 5.2% on a year-over-year basis. Research analysts anticipate that Medtronic will post 5.44 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

MDT has been the subject of several recent research reports. Daiwa America raised Medtronic to a "strong-buy" rating in a report on Friday, August 23rd. UBS Group upgraded Medtronic from a "sell" rating to a "neutral" rating and boosted their price objective for the company from $76.00 to $90.00 in a research report on Thursday, August 15th. Barclays boosted their price objective on Medtronic from $104.00 to $105.00 and gave the company an "overweight" rating in a research report on Thursday, August 22nd. Piper Sandler boosted their price objective on Medtronic from $85.00 to $90.00 and gave the company a "neutral" rating in a research report on Wednesday, August 21st. Finally, Evercore ISI boosted their price objective on Medtronic from $100.00 to $104.00 and gave the company an "outperform" rating in a research report on Tuesday, October 1st. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating, six have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $95.80.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.